About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 247152, 8 pages
http://dx.doi.org/10.1155/2013/247152
Review Article

18F-FDG PET in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma

1Department of Neurological Surgery, Faculty of Medicine, Kagawa University, 1750-1 Miki-cho, Kita-gun, Kagawa 761-0793, Japan
2Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Miki-cho, Kita-gun, Kagawa 761-0793, Japan

Received 13 March 2013; Accepted 2 June 2013

Academic Editor: Eng-Yen Huang

Copyright © 2013 Nobuyuki Kawai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Olson, C. A. Janney, R. D. Rao et al., “The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis,” Cancer, vol. 95, no. 7, pp. 1504–1510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Behin, K. Hoang-Xuan, A. F. Carpentier, and J.-Y. Delattre, “Primary brain tumours in adults,” The Lancet, vol. 361, no. 9354, pp. 323–331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, and J.-Y. Delattre, “Primary brain tumours in adults,” The Lancet, vol. 379, pp. 1984–1996, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. N. S. Kadan-Lottick, M. C. Skluzacek, and J. G. Gurney, “Decreasing incidence rates of primary central nervous system lymphoma,” Cancer, vol. 95, no. 1, pp. 193–202, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. P. C. O'Brien, D. E. Roos, G. Pratt et al., “Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group),” International Journal of Radiation Oncology Biology Physics, vol. 64, no. 2, pp. 408–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan, “Primary CNS lymphoma in immunocompetent patients,” Oncologist, vol. 14, no. 5, pp. 526–539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. E. Abrey, L. Ben-Porat, K. S. Panageas et al., “Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5711–5715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Bataille, V. Delwail, E. Menet et al., “Primary intracerebral malignant lymphoma: report of 248 cases,” Journal of Neurosurgery, vol. 92, no. 2, pp. 261–266, 2000. View at Scopus
  9. W. Küker, T. Nägele, A. Korfel et al., “Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients,” Journal of Neuro-Oncology, vol. 72, no. 2, pp. 169–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. I. S. Haldorsen, J. Krakenes, B. K. Krossnes, O. Mella, and A. Espeland, “CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989–2003,” American Journal of Neuroradiology, vol. 30, no. 4, pp. 744–751, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Boado, K. L. Black, and W. M. Pardridge, “Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors,” Molecular Brain Research, vol. 27, no. 1, pp. 51–57, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. S. N. Reske, K. G. Grillenberger, G. Glatting et al., “Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma,” Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1344–4348, 1997. View at Scopus
  13. L.-C. Ong, Y. Jin, I.-C. Song, S. Yu, K. Zhang, and P. K. H. Chow, “2-[18F]-2-deoxy-D-Glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II,” Acta Radiologica, vol. 49, no. 10, pp. 1145–1153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Paudyal, N. Oriuchi, P. Paudyal et al., “Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma,” Annals of Nuclear Medicine, vol. 22, no. 1, pp. 83–86, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Kosaka, T. Tsuchida, H. Uematsu, H. Kimura, H. Okazawa, and H. Itoh, “18F-FDG PET of common enhancing malignant brain tumors,” American Journal of Roentgenology, vol. 190, no. 6, pp. W365–W369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Kawai, H.-N. Zhen, K. Miyake, Y. Yamamaoto, Y. Nishiyama, and T. Tamiya, “Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment,” Journal of Neuro-Oncology, vol. 100, no. 2, pp. 225–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Kawase, Y. Yamamoto, R. Kameyama, N. Kawai, N. Kudomi, and Y. Nishiyama, “Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma,” Molecular Imaging and Biology, vol. 13, no. 6, pp. 1284–1289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Makino, T. Hirai, H. Nakamura et al., “Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study,” Annals of Nuclear Medicine, vol. 25, no. 6, pp. 432–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. S. Rosenfeld, J. M. Hoffman, R. E. Coleman, M. J. Glantz, M. W. Hanson, and S. C. Schold, “Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography,” Journal of Nuclear Medicine, vol. 33, no. 4, pp. 532–536, 1992. View at Scopus
  20. H. Palmedo, H. Urbach, H. Bender et al., “FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 2, pp. 164–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Hoffman, H. A. Waskin, T. Schifter et al., “FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS,” Journal of Nuclear Medicine, vol. 34, no. 4, pp. 567–575, 1993. View at Scopus
  22. K. Villringer, H. Jager, M. Dichgans et al., “Differential diagnosis of CNS lesions in AIDS patients by FDG-PET,” Journal of Computer Assisted Tomography, vol. 19, no. 4, pp. 532–536, 1995. View at Scopus
  23. M. J. O'Doherty, S. F. Barrington, M. Campbell, J. Lowe, and C. S. Bradbeer, “PET scanning and the human immunodeficiency virus-positive patient,” Journal of Nuclear Medicine, vol. 38, no. 10, pp. 1575–1583, 1997. View at Scopus
  24. R. Hustinx, R. J. Smith, F. Benard, A. Bhatnagar, and A. Alavi, “Can the standardized uptake value characterize primary brain tumors on FDG-PET?” European Journal of Nuclear Medicine, vol. 26, no. 11, pp. 1501–1509, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Dethy, S. Goldman, S. Blecic, A. Luxen, M. Levivier, and J. Hildebrand, “Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma,” Journal of Nuclear Medicine, vol. 35, no. 7, pp. 1162–1166, 1994. View at Scopus
  26. N. Tsuyuguchi, I. Sunada, K. Ohata et al., “Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine,” Annals of Nuclear Medicine, vol. 17, no. 1, pp. 47–51, 2003. View at Scopus
  27. C. Schiepers, P. van Hecke, R. Vandenberghe et al., “Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis,” Multiple Sclerosis, vol. 3, no. 1, pp. 8–17, 1997. View at Scopus
  28. R. Kubota, S. Yamada, K. Kubota, K. Ishiwata, N. Tamahashi, and T. Ido, “Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography,” Journal of Nuclear Medicine, vol. 33, no. 11, pp. 1972–1980, 1992. View at Scopus
  29. P. N. Plowman, C. A. B. Saunders, and M. N. Maisey, “Gliomatosis cerebri: disconnection of the cortical grey matter, demonstrated on PET scan,” British Journal of Neurosurgery, vol. 12, no. 3, pp. 240–244, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Kawai, S. Okubo, K. Miyake et al., “Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings,” Annals of Nuclear Medicine, vol. 24, no. 5, pp. 335–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Z. Tang, T. C. Booth, P. Bhogal, A. Malhotra, and T. Wilhelm, “Imaging of primary central nervous system lymphoma,” Clinical Radiology, vol. 66, no. 8, pp. 768–777, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. E. Abrey, T. T. Batchelor, A. J. M. Ferreri et al., “Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5034–5043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. P. O'Neill, R. P. Dinapoli, P. J. Kurtin, and T. M. Habermann, “Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?” Journal of Neuro-Oncology, vol. 25, no. 1, pp. 67–71, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Jahnke, E. Thiel, P. Martus et al., “Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors,” Journal of Neuro-Oncology, vol. 80, no. 2, pp. 159–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. N. A. Mohile, L. M. Deangelis, and L. E. Abrey, “The utility of body FDG PET in staging primary central nervous system lymphoma,” Neuro-Oncology, vol. 10, no. 2, pp. 223–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Reni, A. J. M. Ferreri, and E. Villa, “Second-line treatment for primary central nervous system lymphoma,” British Journal of Cancer, vol. 79, no. 3-4, pp. 530–534, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Yamanaka, “Management of refractory or relapsed primary central nervous system lymphoma,” Molecular Medicine Reports, vol. 2, no. 6, pp. 879–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Pels, A. Juergens, I. Schirgens et al., “Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma,” Neuro-Oncology, vol. 12, no. 7, pp. 720–724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. N. G. Mikhaeel, M. Hutchings, P. A. Fields, M. J. O'Doherty, and A. R. Timothy, “FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma,” Annals of Oncology, vol. 16, no. 9, pp. 1514–1523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Kawai, Y. Nishiyama, K. Miyake, T. Tamiya, and S. Nagao, “Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis,” Annals of Nuclear Medicine, vol. 19, no. 8, pp. 685–690, 2005. View at Publisher · View at Google Scholar · View at Scopus